Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/80030
Full metadata record
DC FieldValueLanguage
dc.contributor.CRUESPUniversidade Estadual de Campinaspt_BR
dc.typeArtigo de periódicopt_BR
dc.titleImmunophenotyping in Myelodysplastic Syndromes Can Add Prognostic Information to Well-Established and New Clinical Scorespt_BR
dc.contributor.authorReis-Alves, SCpt_BR
dc.contributor.authorTraina, Fpt_BR
dc.contributor.authorHarada, Gpt_BR
dc.contributor.authorCampos, PMpt_BR
dc.contributor.authorSaad, STOpt_BR
dc.contributor.authorMetze, Kpt_BR
dc.contributor.authorLorand-Metze, Ipt_BR
unicamp.author.emaililmetze@unicamp.brpt_BR
unicamp.authorReis-Alves, Suiellen C. Traina, Fabiola Saad, Sara T. O. Lorand-Metze, Irene Univ Estadual Campinas, Hematol & Hemotherapy Ctr, Sao Paulo, Brazilpt_BR
unicamp.authorHarada, Guilherme Campos, Paula M. Saad, Sara T. O. Metze, Konradin Lorand-Metze, Irene Univ Estadual Campinas, Fac Med, Sao Paulo, Brazilpt_BR
dc.subject.wosFlow-cytometric Analysispt_BR
dc.subject.wosScoring Systempt_BR
dc.subject.wosBone-marrowpt_BR
dc.subject.wosHematopoietic-cellspt_BR
dc.subject.wosWorking Conferencept_BR
dc.subject.wosFractal Dimensionpt_BR
dc.subject.wosMyeloid Neoplasmspt_BR
dc.subject.wosSurvivalpt_BR
dc.subject.wosDiagnosispt_BR
dc.subject.wosLeukemiapt_BR
dc.description.abstractBackground: myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic clonal disorders. So, prognostic variables are important to separate patients with a similar biology and clinical outcome. We compared the importance of risk stratification in primary MDS of IPSS and WPSS with the just described revision of IPSS (IPSS-R), and examined if variables obtained by bone marrow immunophenotyping could add prognostic information to any of the scores. Methods: In this prospective study of 101 cases of primary MDS we compared the relation of patients' overall survival with WHO types, IPSS, IPSS-R, WPSS and phenotypic abnormalities of hematopoietic precursors. We examined aberrancies in myelomonocytic precursors and CD34(+) cells. Patients were censored when receiving chemotherapy or BM transplantation. Survival analysis was made by Cox regressions and stability of the models was examined by bootstrap resampling. Results: median age: 64 years (15-93). WHO types: 2 cases of 5q-syndrome, 7 of RA, 64 of RCDM and 28 of RAEB. In the univariate Cox analysis, increasing risk category of all scores, degree of anemia, higher percentage of BM blasts, higher number of CD34(+) cells and their myeloid fractions besides increasing number of phenotypic abnormalities detected were significantly associated with a shorter survival. In the multivariate analysis comparing the three scores, IPSS-R was the only independent risk factor. Comparing WPSS with phenotypic variables (CD34(+)/CD13(+) cells, CD34(+)/CD13(-) cells and 'total alterations') the score and 'CD34(+)/CD13(+) cells' remained in the model. When IPSS was tested together with these phenotypic variables, only 'CD34(+)/CD13(+) cells', and 'total alterations' remained in the model. Testing IPSS-R with the phenotypic variables studied, only the score and 'CD34(+)/CD13(+) cells' entered the model. Conclusions: Immunophenotypic analysis of myelomonocytic progenitors provides additional prognostic information to all clinical scores studied. IPSS-R improved risk stratification in MDS compared to the former scores.pt
dc.relation.ispartofPlos Onept_BR
dc.relation.ispartofabbreviationPLoS Onept_BR
dc.publisher.citySan Franciscopt_BR
dc.publisher.countryEUApt_BR
dc.publisherPublic Library Sciencept_BR
dc.date.issued2013pt_BR
dc.date.monthofcirculationDEC 6pt_BR
dc.identifier.citationPlos One. Public Library Science, v. 8, n. 12, 2013.pt_BR
dc.language.isoenpt_BR
dc.description.volume8pt_BR
dc.description.issuenumber12pt_BR
dc.rightsabertopt_BR
dc.sourceWeb of Sciencept_BR
dc.identifier.issn1932-6203pt_BR
dc.identifier.wosidWOS:000328566700027pt_BR
dc.identifier.doi10.1371/journal.pone.0081048pt_BR
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)pt_BR
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)pt_BR
dc.description.sponsorshipFAEPEX (Research Fund of the University of Campinas) [proc 1208/11]pt_BR
dc.description.sponsorshipMDS Foundationpt_BR
dc.description.sponsorship1Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)pt_BR
dc.description.sponsorship1Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)pt_BR
dc.description.sponsordocumentnumberFAPESP [proc. 04/08882-3]pt
dc.description.sponsordocumentnumberCNPq [proc.2008-57895/1]pt
dc.description.sponsordocumentnumberFAEPEX (Research Fund of the University of Campinas) [proc 1208/11]pt
dc.description.sponsordocumentnumberCNPq [302277/2009-9, proc 307270/2010-6, 301483/2008-6]pt
dc.date.available2014-08-01T18:30:56Z
dc.date.available2015-11-26T17:54:24Z-
dc.date.accessioned2014-08-01T18:30:56Z
dc.date.accessioned2015-11-26T17:54:24Z-
dc.description.provenanceMade available in DSpace on 2014-08-01T18:30:56Z (GMT). No. of bitstreams: 0 Previous issue date: 2013en
dc.description.provenanceMade available in DSpace on 2015-11-26T17:54:24Z (GMT). No. of bitstreams: 0 Previous issue date: 2013en
dc.identifier.urihttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/80030
dc.identifier.urihttp://repositorio.unicamp.br/jspui/handle/REPOSIP/80030-
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.